

**Trial Nation**  
Clinical Trials Denmark



DANISH DEMENTIA  
RESEARCH CENTRE

## CENTER FOR DEMENTIA

A network of Danish memory clinics

*Your clinical research partner within Alzheimer's  
disease and other dementia diseases.*

---

# *Trial Nation Center for Dementia a network of Danish Memory Clinics*

---

*Trial Nation Center for Dementia is a collaboration of Danish memory clinics with experience in clinical research with investigational medicinal products in Alzheimer's disease, Huntington's disease and other neurodegenerative disorders.*

*The network was established in 2018 based on a preexisting research network of memory clinics initially developed in a large randomized controlled national multicenter clinical trial on physical exercise in patients with mild Alzheimer's disease (ADEX).*

*The five memory clinics successfully collaborated on and completed this complex intervention trial with 200 patients<sup>1,2</sup>, which has further developed and strengthened their capacity for conducting clinical drug trials.*

*As members of the world-wide observational study on Huntington's disease, the Enroll-HD*

*study<sup>3</sup> (<https://enroll-hd.org>), three of the memory clinics also have extensive experience with systematic longitudinal outcome assessments in patients with Huntington's disease, which has contributed to widening of the target group of patients in the network.*

*In 2023, the center was expanded with one regional network clinic. The regional clinic is an emerging research site within the area of Alzheimer's disease and other neurodegenerative disorders.*

*The main purpose of Center for Dementia is to facilitate clinical trials regarding pharmacological interventions and application of new medical technology in the diagnosis and treatment of neurodegenerative cognitive disorders.*

*Center for Dementia offers one point of contact to the center and network.*

*For coordinated request to all clinics please contact:*

---

*Kristian Steen Frederiksen  
Feasibility Coordinator, Trial Nation  
Clinical trials director, MD  
Danish Dementia Research Center  
Dept. of Neurology, Rigshospitalet  
[Kristian.steen.frederiksen@regionh.dk](mailto:Kristian.steen.frederiksen@regionh.dk)  
+45 35 61 46*

*Kirsten Bødker  
Center Facilitator, Trial Nation  
[kib@trialnation.dk](mailto:kib@trialnation.dk)  
+45 40 75 08 53*

# Overview of Trial Nation Memory clinics

<i>Table 1: DANISH MEMORY CLINICS PARTICIPATING IN TRIAL NATION Center for Dementia</i>	<i>REGION</i>
<i>Danish Dementia Research Centre, Dept. of Neurology, Rigshospitalet, University of Copenhagen</i>	<i>Capital Region of Denmark</i>
<i>Dementia Research Centre, Dept. of Neurology, Zealand University Hospital</i>	<i>Region Zealand</i>
<i>Dementia Clinic Dept. of Neurology, Odense University Hospital, Odense &amp; Svendborg</i>	<i>Region of Southern Denmark</i>
<i>Dementia Clinic, Dept. of Neurology, Aarhus University Hospital</i>	<i>Central Denmark Region</i>
<i>Dementia Clinic, Dept. of Neurology, Aalborg University Hospital</i>	<i>The North Denmark Region</i>
<i>Danish Memory Clinics participating in Trail Nation Network for Dementia</i>	<i>REGION</i>
<i>Dementia Clinic, Dept. of Neurology, Esbjerg Hospital</i>	<i>Region of Southern Denmark</i>



1. Aalborg University hospital
2. Aarhus University Hospital
3. Odense University Hospital
4. Odense University Hospital, Svendborg
5. Zealand University Hospital
6. Rigshospitalet, University of Copenhagen
7. Esbjerg Hospital

Figure 1. Dementia clinics across Denmark.

● Center clinics ● Network clinics

# Patients

---

*A wide range of neurodegenerative disorders*

*The memory clinics in the Trial Nation Center and Network for Dementia have access to patient cohorts with a wide range of disorders, including:*

- *Alzheimer's disease*
- *Vascular dementia*
- *Dementia with Lewy bodies*
- *Parkinson's disease with dementia*
- *Frontotemporal dementia.*
- *Mild cognitive impairment, including prodromal Alzheimer's disease*
- *Subjective cognitive decline*
- *Huntington's disease*
- *Spinocerebellar ataxia*
- *Hereditary spastic paraparesis*

## *Large well-characterized cohorts*

*The routine extensive diagnostic work-up and biomarker-based diagnostic workflow in early phase neurodegenerative disorders, enables the memory clinics to have access to well-characterized patient cohorts from which participants for clinical trials can be recruited.*

*According to the national quality registry for diagnostic evaluation of dementia, DanDem<sup>1</sup>, 9.000-10.000 patients with cognitive symptoms or dementia are referred annually to Danish memory clinics. About 50% of them are referred to the 6 memory clinics in Trial Nation Center and Network for Dementia .*

## *Alzheimer's disease*

*Approximately 35% of all referred patients are diagnosed with Alzheimer's disease dementia and 20% with Mild Cognitive Impairment (including prodromal Alzheimer's disease).*

*Patients with Mild Cognitive Impairment and Alzheimer's disease are seen on follow-up during a variable length of time in the participating memory clinics.*

## *Huntington's disease*

*Defined by the Danish Health Authority, the management of patients with Huntington's disease is a specialized function centralized in 3 neurological departments in Denmark (Aarhus University Hospital, Odense University Hospital and Copenhagen University Hospital - Rigshospitalet) who see in total approximately 500 patients with symptomatic Huntington's disease, including approximately 100 individuals with presymptomatic Huntington's disease on a regular basis.*

*Many of these participate in the Enroll-HD study, a worldwide observational study for Huntington's disease families. Thus, recruitment to drug trials may be based on access to detailed information on patients in the database.*

*All 3 sites with Huntington's disease patients have access to state-of-the-art molecular genetics laboratories with experience in the genetic diagnostic procedures.*

---

<sup>1</sup> <https://www.rkkp.dk/kvalitetsdatabaser/databaser/dansk-klinisk-kvalitetsdatabase-for-demens>

# Trial experience and capacity

---

*Based in clinical neurology, participating memory clinics have up to 25 years of experience in conducting clinical trials from more than 40 phase I-IV studies, with the inclusion of more than 300 patients with various neurodegenerative disorders.*

*We have a successful track record for timely delivery of high-quality data from clinical trials. For more information see table 1.*

*Trial participants diagnosed in a specialized clinical setting with trained staff*

*Trial participants are mainly recruited from the cohorts of patients already on the memory clinic lists. The majority of the staff responsible for the recruitment of patients and for the conduction of clinical trials have clinical experience from memory clinics and trial experience from previous clinical trials.*

*Biomarker based diagnoses with frequent use of lumbar puncture*

*All memory clinics in the network are based in neurology, and assessment of brain imaging biomarkers as well as lumbar puncture is used*

*on a routine basis in patients referred for diagnostic work-up of cognitive impairment.*

*Access to state-of-the art brain imaging techniques*

*All memory clinics in the network have access to MRI and FDG-PET on site, and some have also access to amyloid- and tau-PET.*

*Low screening failure rate*

*Due to the access to well-characterized patient cohorts, and the extensive experience in managing patients with Alzheimer, Huntington's disease and other neurodegenerative disorders, the network has a relatively low screen failure rate compared to international standards, with a median around 30 %, for previous and current trials.*

*High retention rate*

*As most patients are already in contact with the memory clinics, patient cooperation can be taken into account in the recruitment process, leading to a relatively high retention rate (70 % - 100 %).*

# Overview of the memo clinics in Center and Network for Dementia

## Access to investigations

Table 2:

Clinic	Patients	Phase	CSF biomarkers	MRI	FDG PET	Amyloid PiB-PET	Tau PET	PET MRI	Gene testing	Contact
Danish Dementia Research Centre Dept. of Neurology Rigshospitalet University of Copenhagen	AD, DLB, FTD, HD, MCI, PDD, VAD, SCD, SCA	Phase I, FIH, II, III, IV	+	+	+	+	+	+	+	Director of Clinical Trial Unit, consultant neurologist Kristian Steen Frederiksen <a href="mailto:kristian.steen.frederiksen@regionh.dk">kristian.steen.frederiksen@regionh.dk</a>  For Huntington's Disease: Consultant neurologist Lena Hjermind <a href="mailto:lena.elisabeth.hjermind.01@regionh.dk">lena.elisabeth.hjermind.01@regionh.dk</a>
Dementia Research Centre, Dept. of Neurology, Zealand University Hospital	AD, DLB, FTD, MCI, PDD, VAD, SCD	Phase II, III, IV	+	+	+	(+)	(+)	(+)	+	Ass. Professor, Consultant neurologist, Peter Høgh <a href="mailto:pjh@regionsjaelland.dk">pjh@regionsjaelland.dk</a>
Dementia Clinic Department of Neurology, Odense University Hospital, Odense & Svendborg	AD, DLB, FTD, HD, MCI, PDD, VAD	Phase II, III, IV	+	+	+	+		+	+	Consultant psychiatrist Rune Ladeby Erichsen <a href="mailto:rune.ladeby.erichsen@rsyd.dk">rune.ladeby.erichsen@rsyd.dk</a>  For Huntington's Disease: Professor, Consultant neurologist Morten Blaabjerg <a href="mailto:morten.blaabjerg1@rsyd.dk">morten.blaabjerg1@rsyd.dk</a>
Dementia Clinic, Dept. of Neurology, Aarhus University Hospital	AD, DLB, FTD, HD, MCI, PDD, VAD, SCA	Phase II, III, IV	+	+	+	+	+	+	+	Consultant neurologist Hanne Gottrup <a href="mailto:hannegottrup@rm.dk">hannegottrup@rm.dk</a>  For Huntington's disease: Neurologist Jan Lykke Scheel Thomsen <a href="mailto:jathms@rm.dk">jathms@rm.dk</a>
Dementia Clinic, Dept. of Neurology, Aalborg University Hospital	AD, DLB, FTD, (HD), MCI, PDD, VAD	Phase II, III, IV	+	+	+				+	Consultant neurologist Karsten Vestergaard <a href="mailto:k.vestergaard@rm.dk">k.vestergaard@rm.dk</a>
Dementia Clinic, Dept. of Neurology Esbjerg Hospital	AD, DLB, FTD, MCI, PDD, VAD, SCD	Phase II, III, IV	+	+	+	+	+	(+)	+	Consultant neurologist Tobias Sejbaek <a href="mailto:Tobias.Sejbaek@rsyd.dk">Tobias.Sejbaek@rsyd.dk</a>

Note: AD = Alzheimer's disease; CSF = cerebrospinal fluid; DLB = Dementia with Lewy bodies; FDG PET = fluorodeoxyglucose Positron Emission Tomography; FTD = FrontoTemporal Dementia; HD = Huntington's disease; MCI = Mild Cognitive Impairment; MRI = Magnetic Resonance Imaging; PDD = Parkinson's Disease Dementia; PiB = Pittsburgh compound B; VAD = VAscular Dementia; SCA = Spino Cerebellar Ataxia; SCD = Subjective Cognitive Decline.

"+" = method available in-house; "(+)" = method available via collaboration with other hospitals.

# Harmonized diagnostic criteria

The memory clinics constituting the Trial Nation Center and Network for Dementia collaborate on:

- A uniform set of diagnostic criteria for specific neurodegenerative disorders (see table 3).
- Standardized analysis of blood and cerebrospinal fluid (CSF) – compliant with the Alzheimer’s Association quality control program for CSF biomarkers.

- harmonization initiatives and clinical rater training at annual network meetings
- Preferred minimum set of rating scales in relation to diagnostic work-up and regular clinical reassessments.

The clinics have experience with several other instruments and scales as well (see table 4).

**Table 3: DIAGNOSTIC CRITERIA USED IN CLINICAL PRACTICE**

Diagnosis	Diagnostic criteria
Dementia	National Institute of Aging and Alzheimer’s Association (NIA-AA) workgroup criteria (2011) <sup>4*</sup>
Mild Cognitive Impairment	Winblad criteria (2004) <sup>5</sup>
Mild Cognitive Impairment due to Alzheimer’s disease	National Institute of Aging and Alzheimer’s Association (NIA-AA) workgroup criteria (2011) <sup>6*</sup>
Alzheimer’s disease dementia	National Institute of Aging and Alzheimer’s Association (NIA-AA) workgroup criteria (2011) <sup>4*</sup>
Vascular dementia	The International Society for Vascular Behavioral and Cognitive Disorders (VASCOG) criteria (2014) <sup>7</sup>
Dementia with Lewy bodies	Fourth consensus report of the DLB Consortium (2017) <sup>8</sup>
Behavioural variant frontotemporal dementia	Revised diagnostic criteria for the behavioural variant of frontotemporal dementia (2011) <sup>9</sup>
Language variants frontotemporal dementia	Classification of primary progressive aphasia and its variants (2011) <sup>10</sup>
Huntington’s disease	Diagnostic Criteria for Huntington’s Disease Based on Natural History (2014) <sup>11</sup>

\* Centers also have experience with the NIA-AA 2018 AD criteria

**Table 4: CLINICAL OUTCOME MEASURES USED IN CLINICAL PRACTICE**

Outcome	Scale
Global function	Clinical Dementia Rating (CDR) <sup>12</sup>
Cognition	Mini-Mental State Examination (MMSE) <sup>13</sup> Rowland Universal Dementia Assessment (RUDAS) <sup>14</sup> Addenbrook Cognitive examination (ACE) <sup>15</sup>
Activities of daily living	Disability Assessment for Dementia (DAD) <sup>16</sup> Functional Assessment Questionnaire (FAQ-IADL) <sup>17</sup>
Mood	Geriatric Depression Scale 15 items (GDS-15) <sup>18</sup> Major Depression Inventory (MDI) <sup>19</sup>
Neuropsychiatric symptoms	Neuropsychiatric Inventory - questionnaire (NPI-Q) <sup>20</sup>
Motor Symptoms in Huntington's disease	Unified Huntington's Disease rating scale - movement (UHDRSm) <sup>21</sup>

Updates regarding Center for Dementia are posted on:

- [www.trialnation.dk](http://www.trialnation.dk)
- [www.linkedin.com/in/trialnation](http://www.linkedin.com/in/trialnation)

## REFERENCES

1. Hoffmann K, Frederiksen KS, Sobol NA, et al. Preserving Cognition, Quality of Life, Physical Health and Functional Ability in Alzheimer's Disease: The Effect of Physical Exercise (ADEX Trial): Rationale and Design. *Neuroepidemiology*. 2013;41:198-207.
2. Hoffmann K, Sobol NA, Frederiksen KS, et al. Moderate-to-high intensity physical exercise in patients with Alzheimer's disease: A randomized controlled trial. *J Alzheimer's Dis*. 2016;50:443-453.
3. Landwehrmeyer GB, Fitzer-Attas CJ, Giuliano JD, et al. Data Analytics from Enroll-HD, a Global Clinical Research Platform for Huntington's Disease. *Mov Disord Clin Pract*. 4:212-224.
4. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging and the Alzheimer's Association workgroup. *Alzheimer's Dement*. 2011;7:263-269.
5. Winblad B, Palmer K, Kivipelto M, et al. Mild cognitive impairment - Beyond controversies, towards a consensus: Report of the International Working Group on Mild Cognitive Impairment. *J Intern Med*. 2004;256:240-246.
6. Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimer's Dement*. 2011;7:270-279.
7. Sachdev P, Kalaria R, O'Brien J, et al. Diagnostic Criteria for Vascular Cognitive Disorders: A VASCOG Statement. *Alzheimer Dis Assoc Disord*. 2014;00:1-13.



8. Mckeith IG, Sci M, Boeve BF, et al. *Diagnosis and management of dementia with Lewy bodies Fourth consensus report of the DLB Consortium.* 2017; 89:88-100.
9. Rascovsky K, Hodges JR, Knopman D, et al. *Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia.* *Brain.* 2011;134:2456-2477. d
10. Gorno-Tempini M, Hillis A, Weintraub S. *Classification of primary progressive aphasia and its variants.* *Neurology.* 2011; 76:1006-14.
11. Reilmann R, Leavitt BR, Ross CA. *Diagnostic criteria for Huntington's disease based on natural history.* *Mov Disord.* 2014;29:1335-1341.
12. Hughes CP, Berg L, Danziger W, Coben LA, Martin RL. *A New Clinical Scale for the Staging of Dementia.* *Br J Psychiatry.* 1982;140:566-572.
13. Folstein M, Folstein S. "Mini-Mental State" A practical method for grading the cognitive state of patients for the clinician. *J Psychiat Res.* 1975;12:189-198.
14. Storey JE, Rowland JTJ, Conforti DA, Dickson HG. *The Rowland Universal Dementia Assessment Scale (RUDAS): a multicultural cognitive assessment scale.* *Int Psychogeriatrics.* 2004;16:13-31.
15. Mathuranath PS, Nestor PJ, Berrios GE, Rakowicz W, Hodges JR. *A brief cognitive test battery to differentiate Alzheimer's disease and frontotemporal dementia.* *Neurology.* 2000;55:1613-1620.
16. Gelinas I, Gauthier L, McIntyre M, Gauthier S. *Development of a Functional Measure for Persons With Alzheimer's Disease: The Disability Assessment for Dementia.* *Am J Occup Ther.* 1999;53:471-481.
17. Pfeffer RI, Kurosaki TT, Harrah CH, Chance JM, Filos S. *Measurement of Functional Activities in Older Adults in the Community.* *J Gerontol.* 1982;37:323-329.
18. Sheikh JI, Yesavage JA, Brooks JO, et al. *Proposed Factor Structure of the Geriatric Depression Scale.* *Int Psychogeriatrics.* 1991;3:23-28.
19. Bech P, Rasmussen NA, Olsen LR, Noerholm V, Abildgaard W. *The sensitivity and specificity of the Major Depression Inventory, using the Present State Examination as the index of diagnostic validity.* *J Affect Disord.* 2001;66:159-164.
20. Kaufer DI, Cummings JL, Ketchel P, et al. *Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory.* *J Neuropsychiatry Clin Neurosci.* 2000;12:233-239.
21. *Unified Huntington's disease rating scale: Reliability and consistency.* *Mov Disord.* 1996;11:136-1